298 patents
Page 3 of 15
Utility
Process and Intermediates for Preparing a Jak Inhibitor
23 Feb 23
The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
Filed: 11 Jul 22
Utility
PIPERIDIN-4-YL Azetidine Derivatives As JAK1 Inhibitors
9 Feb 23
The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Taisheng Huang, Chu-Biao Xue, Hui-Yin Li, Qun Li, Anlai Wang, Lingquan Kong, Hai Fen Ye, Wenqing Yao, James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
Filed: 17 Feb 22
Utility
Pyrazolopyridines and Triazolopyridines As A2A / A2B Inhibitors
2 Feb 23
Taisheng Huang, Xiaozhao Wang
Filed: 15 Jun 22
Utility
Biomarkers for Graft-versus-host Disease
26 Jan 23
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor.
Michael D. Howell, Hao Liu, Michael A. Pratta
Filed: 20 May 22
Utility
Imidazolyl Pyrimidinylamine Compounds As CDK2 Inhibitors
26 Jan 23
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 29 Jul 22
Utility
HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
12 Jan 23
Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
Filed: 24 Jun 21
Utility
Bicyclic Pyrazolyl Amines As CDK2 Inhibitors
5 Jan 23
Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
Filed: 21 Jun 22
Utility
Tricyclic Heterocycles As FGFR Inhibitors
5 Jan 23
Robert Swyka, Evan Styduhar, Xin Li, Oleg Vechorkin, Wenqing Yao
Filed: 8 Jun 22
Utility
Tricyclic Heterocycles As FGFR Inhibitors
5 Jan 23
Xin Li, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Wenqing Yao
Filed: 8 Jun 22
Utility
Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors
5 Jan 23
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
Filed: 13 Jan 22
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
29 Dec 22
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 8 Jul 22
Utility
AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS
29 Dec 22
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
Filed: 24 May 21
Utility
Derivatives of an FGFR Inhibitor
29 Dec 22
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Ming Tao, Jason Boer
Filed: 22 Jul 22
Utility
HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
15 Dec 22
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 8 Mar 22
Utility
Hetero-bicyclic Inhibitors of Kras
8 Dec 22
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Alexander Sokolsky, Chang Min, Xiaozhao Wang, Wenqing Yao
Filed: 28 Apr 22
Utility
JAK1 Pathway Inhibitors for the Treatment of Prurigo Nodularis
1 Dec 22
This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.
Paul Smith, Kurt Andrew Brown
Filed: 3 May 22
Utility
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
1 Dec 22
This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
Krishna Vaddi
Filed: 20 Dec 21
Utility
Topical Formulation for a Jak Inhibitor
1 Dec 22
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Topical Formulation for a Jak Inhibitor
24 Nov 22
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Multispecific Binding Moieties Comprising Novel PD-1 Binding Domains
17 Nov 22
The present disclosure relates to multispecific binding moieties comprising novel PD-1 binding domains that have a higher binding affinity for human PD-1 than a reference PD-1 binding domain.
Simon Edward PLYTE, Patrick MAYES, Horacio G. NASTRI, Shaun M. STEWART
Filed: 30 Mar 22